Costs and Benefits of Two Doses of Fluphenazine

Stephen R. Marder, Theodore Van Putten, Jim Mintz, Joanne Mckenzie, Malca Lebell, Gary Faltico, Philip R.a. May

Research output: Contribution to journalArticlepeer-review

130 Scopus citations

Abstract

The relative costs and benefits of low- and conventionaldose neuroleptic maintenance therapy were evaluated in a double-blind comparison of 5 and 25 mg of fluphenazine decanoate administered every two weeks. Subjects were 50 patients fulfilling DSM-III criteria for schizophrenic disorder who had been successfully maintained with 25 mg or less of fluphenazine decanoate. A one-year survival analysis disclosed that there were no statistically significant differences between the two doses insofar as preventing relapse. Patients receiving the higher dose appeared to feel more uncomfortable, as indicated by higher scores on subscales of the Hopkins Symptom Checklist-90. In addition, patients receiving the higher dose had higher side-effect scores. These findings suggest that a substantial proportion of patients who are presently maintained with 25 mg or less of fluphenazine decanoate every two weeks will do just as well with as little as 5 mg.

Original languageEnglish (US)
Pages (from-to)1025-1029
Number of pages5
JournalArchives of General Psychiatry
Volume41
Issue number11
DOIs
StatePublished - Nov 1984
Externally publishedYes

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Costs and Benefits of Two Doses of Fluphenazine'. Together they form a unique fingerprint.

Cite this